PARP inhibitors

• US 9,150,628 B2
• Filed: 11/14/2006
• Issued: 10/06/2015
• Est. Priority Date: 11/14/2005
• Status: Expired due to Fees

• Current Assignee: Centre National De La Recherche Scientifique
• Original Assignee: Centre National De La Recherche Scientifique
• Inventors: Hamiche, Ali
• Primary Examiner(s): ROBINSON, HOPE A
• Application Number:
  US12/084,873
• Publication Number:
  US 20100323974A1
• Time in Patent Office: 3,248 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/04 : Immunostimulants
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/08 : Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 14/47 : from mammals

Abstract

The present invention relates to new inhibitors of the nucleic enzyme poly(adenosine 5′-diphospho-ribose) polymerase [“poly(ADP-ribose) polymerase” or “PARP”, which is also sometimes called “PARS” for poly(ADP-ribose) synthetase]. More particularly, the invention relates to the use of PARP inhibitors to prevent and/or treat tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury; neurological disorders and neurodegenerative diseases; to prevent or treat vascular stroke; to treat or prevent cardiovascular disorders; to treat other conditions and/or disorders such as age-related macular degeneration, AIDS and other immune senescence diseases, arthritis, atherosclerosis, cachexia, cancer, degenerative diseases of skeletal muscle involving replicative senescence, diabetes, head trauma, immune senescence, inflammatory bowel disorders (such as colitis and Crohn'"'"'s disease), muscular dystrophy, osteoarthritis, osteoporosis, chronic and acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxic shock), and skin aging; to extend the lifespan and proliferative capacity of cells; to alter gene expression of senescent cells; or to radiosensitize hypoxic tumor cells.

Claims

1. An isolated inhibitor of the nucleic enzyme poly(adenosine 5′

-diphospho-ribose) polymerase (PARP) having phosphoesterase activity, comprising;

an amino acid sequence consisting of macroH2A1.1 (amino acids 121 to 369 of SEQ ID NO;

     1), macroH2A1.2 (amino acids 120 to 371 of SEQ ID NO;

     2), or macroH2A2 (amino acids 121 to 372 of SEQ ID NO;

     3), wherein the amino acid sequence is fused to a heterologous sequence selected from the group consisting of a nuclear localization sequence, a His tag, a GST protein, a FLAG tag, an HA tag, and combinations thereof.

2. The isolated inhibitor of PARP of claim 1, wherein the amino acid sequence is a C-terminal non-histone domain of macroH2A1.1.

3. The isolated inhibitor of PARP of claim 1, wherein the macroH2A1.1, macroH2A1.2, or macroH2A2 do not comprise a macroH2A histone fold domain that is homologous with histone H2A.

4. The isolated inhibitor of PARP of claim 1, wherein the macroH2A1.1, macroH2A1.2, or macroH2A2 comprise the macro domain of a macroH2A histone.

5. The isolated inhibitor of PARP of claim 4, wherein the macro domain of a macroH2A histone is selected from the group consisting of residues 184 to 369 or 202 to 369 of macroH2A1.1 (SEQ ID NO:

1), residues 183 to 371 or 201 to 371 of macroH2A1.2 (SEQ ID NO;

     2), and residues 184 to 372 or 202 to 372 of macroH2A2 (SEQ ID NO;

     3).

6. A composition comprising:

(i) the isolated inhibitor of PARP of claim 1, and

(ii) a pharmaceutically acceptable vehicle.

7. An isolated inhibitor of the nucleic enzyme poly(adenosine 5′

-diphospho-ribose) polymerase (PARP) in a composition for treating neurological disorders, cardiovascular disorders, immune senescence diseases, degenerative diseases, or inflammatory disorders associated with PARP activation, comprising;

a C-terminal non-histone domain of a macroH2A histone having an amino acid sequence consisting of macroH2A1.1 (amino acids 121 to 369 of SEQ ID NO;

     1), macroH2A1.2 (amino acids 120 to 371 of SEQ ID NO;

     2), or macroH2A2 (amino acids 121 to 372 of SEQ ID NO;

     3) histone, wherein the amino acid sequence is fused to a nuclear localization sequence, a His tag, a GST protein, a FLAG tag, an HA tag, or a combination thereof.

8. The isolated inhibitor of PARP of claim 7, wherein the C-terminal non-histone domain of macroH2A histone is macroH2A1.1.

9. The isolated inhibitor of PARP of claim 7 wherein the macroH2A1.1, macroH2A1.2, or macroH2A2 do not comprise a macroH2A histone fold domain that is homologous with histone H2A.

10. The isolated inhibitor of PARP of claim 7, wherein the amino acid sequence consists of residues 184 to 369 or 202 to 369 of macroH2A1.1 (SEQ ID NO:

1), residues 183 to 371 or 201 to 371 of macroH2A1.2 (SEQ ID NO;

     2), or residues 184 to 372 or 202 to 372 of macroH2A2 (SEQ ID NO;

     3).

11. The isolated inhibitor of PARP of claim 7, comprising a pharmaceutically acceptable vehicle.

12. An isolated inhibitor of the nucleic enzyme poly(adenosine 5′

-diphospho-ribose) polymerase (PARP) having phosphoesterase activity, comprising;

a C-terminal non-histone domain of a macroH2A histone fused to at least one heterologous sequence, wherein the C-terminal non-histone domain of the macroH2A histone has an amino acid sequence consisting of macroH2A1.1 (amino acids 121 to 369 of SEQ ID NO;

1) and the heterologous sequence is selected from the group consisting of a nuclear localization sequence, a His tag, a GST protein, a FLAG tag, an HA tag, and combinations thereof.

13. An isolated inhibitor of the nucleic enzyme poly(adenosine 5′

-diphospho-ribose) polymerase (PARP) having phosphoesterase activity, comprising;

an amino acid sequence consisting of residues 184 to 369 or 202 to 369 of human macroH2A1.1 (SEQ ID NO;

     1), residues 183 to 371 or 201 to 371 of human macroH2A1.2 (SEQ ID NO;

     2), or residues 184 to 372 or 202 to 372 of human macroH2A2 (SEQ ID NO;

     3), wherein the amino acid sequence is fused to a heterologous sequence selected from the group consisting of a nuclear localization sequence, a His tag, a GST protein, a FLAG tag, an HA tag, and combinations thereof.